Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. Its clinical trial program includes human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB), a Barbados company, and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncolytics Biotech (U.K.) are subsidiaries of OBB.